In line with LivaNova’s mission, the Company develops innovative products that deliver life-changing improvements for patients, and the approach to quality starts and ends with patient and customer safety. LivaNova is dedicated to complying with all laws, standards, and regulations regarding quality, safety, and performance.
One hundred percent of LivaNova manufacturing and R&D facilities are ISO 13485 certified, i.e. the International Organization for Standardization’s quality management system standard for medical devices. LivaNova also complies with all applicable regulations and/or legislations in jurisdictions where it operates, including but not limited to the European medical legislative requirements (Directive 93/42/EEC and Medical Device Regulation 2017/745), the US FDA Quality System Regulations for medical devices (21 CFR part 820), Japan MHLW Ministerial Ordinance No.169, Canadian Medical Device Regulations (SOR/98-282), Brazil ANVISA – RDC No.16/2013, and the Australian Therapeutic Goods (Medical Devices) Regulations 2002 (TGA). In addition, LivaNova’s manufacturing sites in Italy and Germany are certified to the ISO 14001 international standard for designing and implementing an environmental management system (EMS) and the ISO 45001 international standard for the management of the occupational health and safety system.
Products
Quality in Everything We Do
Quality in Everything We Do
Our Global Impact(1)
145,000+ PATIENTS treated with VNS TherapyTM |
44,000+ CHILDREN treated with VNS TherapyTM |
4M+ PATIENTS treated with InspireTM oxygenator |
522,000+ NEW PATIENTS treated with InspireTM oxygenator in 2024 |
50+ YEARS of perfusion know-how and worldwide leadership with S5TM HLM and EssenzTM Perfusion System |
75,000+(2) PATIENTS treated with EssenzTM Perfusion System |
5M+ PATIENTS treated with XTRATM Autotransfusion System |
3% increase of PATIENTS treated with XTRATM Autotransfusion System |
(1) Updated April 10, 2025
(2) Calculated based on Essenz™ Perfusion System installed and considering 1 procedure/day, 4 days/week.
What We Are Doing

Facility Compliance

LivaNova’s Quality Management System

Product Performance

Information Security & Privacy
Facility Compliance
LivaNova sites undergo audits by regulatory authorities and notified bodies on a regular basis to verify compliance with the regulations in all the geographies in which the Company distributes products. This includes regular inspections by the U.S. FDA. No Warning Letter has been issued to a LivaNova site within the last 3 years.
FY22 | FY23 | FY24 | |
---|---|---|---|
FDA Warning Letters | 0 | 0 | 0 |
(1) Updated April 10, 2025
LivaNova’s Quality Management System
LivaNova’s Quality Management System (QMS) is designed to build quality into products at every stage of the lifecycle, starting with the design and development of its products all the way through the manufacturing, testing, distribution, and post-market surveillance stages.
Employee Training
- All employees who oversee product quality complete training on quality control, product safety, and/or QMS, at onboarding, and thereafter annually, or with varying frequency based on criticality. The effectiveness of employee compliance training is monitored and tracked through an electronic training record system.
Supplier Management
- All parts and components not made in-house are sourced from approved suppliers and monitored by LivaNova’s Supplier Quality team. The team is trained to the Company's rigorous supplier quality processes and standards, which outline requirements in selecting, qualifying, managing, and monitoring suppliers to ensure that all purchased or subcontracted products and services are controlled and conform to a high standard.
- LivaNova follows a rigorous process to monitor suppliers that are considered high risk, as per the Company’s QMS risk assessment process. The monitoring is rigorous to ensure compliance with the Company’s QMS and applicable regulations.
- Ongoing engagement and collaboration on process improvements to further drive innovation, sustainability, and patient safety is prioritized. For example, in 2024, LivaNova engaged all high-risk, direct material and component suppliers to participate in educational workshops on the Company’s QMS and production process controls, which provided insight into how supplied materials and components impact the Company’s devices and patients. During the workshops, LivaNova collected feedback from suppliers and shared the Company’s sustainability objectives, including its targets for reducing its carbon footprint and enhancing social responsibility, with the goal of collaboratively building a sustainable supply chain.
Product Performance
As part of LivaNova’s QMS, the Company’s Corrective and Preventative Actions (CAPA) program embeds robust processes to identify and resolve potential issues. The risk management process follows the ISO 14971 international standard for medical devices, which ensures the safety and effectiveness of the devices for their intended use.
LivaNova monitors the use and performance of the products distributed to the market through a post-market surveillance system, which gathers customer feedback. This data is collected through the Company’s global complaint handling process as well as through medical and clinical literature review and post-market clinical data collection activities. Further, when the Company is alerted to potential safety concerns, LivaNova takes immediate corrective action through the embedded QMS correction and removal process.
Product Performance governance is led by cross-functional leaders from LivaNova’s Medical Affairs, Supplier Quality, and Statistic and Data Science teams.
FY22 | FY23 | FY24 | |
---|---|---|---|
FDA Class I Recalls Initiated | 2 | 0 | 0 |
FDA Class II Recalls Initiated | 0 | 2 | 2 |
FDA Class III Recalls Initiated | 0 | 0 | 0 |
(1) Updated April 10, 2025

Information Security & Privacy
LivaNova endeavors to bring the latest technology to all products in a safe and secure manner. In doing so, the Company strives to integrate both privacy and information security into both its products and services. LivaNova is subject to various local and international laws that protect the privacy and confidentiality of patient health information, including patient medical records, and that restricts the use and disclosure of this information. LivaNova works to comply with various privacy standards and to adapt its business processes to ensure that the safety of its products and the security of patient information remain at the Company’s core.
LivaNova has dedicated resources and processes to help prevent, detect, and respond to cyber threats. The information security team, led by the Chief Information Security Officer (CISO), manages the Company’s Information Security Management System (ISMS) with the objective of strengthening cyber resiliency. LivaNova’s ISMS strengthening plans consider leading industry standards, such as the National Institute of Standards and Technology (NIST) cybersecurity framework, the ISO 27001 international standard for information security management system standard, the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and other security controls to apply across the business.
Other Sustainability Focus Areas
Corporate Governance
Our Board of Directors and executive leadership team ensure accountability, transparency and fairness throughout the company. Governance practices influence our corporate strategy, business operations, environmental impacts, ethics & integrity, compensation and management of risk. The Board continually considers corporate governance improvements and models a culture of compliance.